Autologous, hapten-modified vaccine as a treatment for human cancers.

Berd, D; Kairys, J; Dunton, C; Mastrangelo, M J; Sato, T; Maguire, H C

Berd, D; Kairys, J; Dunton, C; Mastrangelo, M J; Sato, T; Maguire, H C.

Affiliation

Berd D; Department of Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA.

Semin Oncol ; 25(6): 646-53, 1998 Dec.

Article in En | MEDLINE | ID: mdl-9865679

Subject(s)

Cancer Vaccines; Dinitrobenzenes/immunology; Haptens/immunology; Immunotherapy, Active; Melanoma/therapy; Animals; Clinical Trials as Topic; Female; Humans; Hypersensitivity, Delayed; Inflammation; Lung Neoplasms/therapy; Male; Melanoma/immunology; Melanoma/secondary; Mycobacterium bovis; Neoplasm Metastasis/immunology; Neoplasm Metastasis/pathology; Ovarian Neoplasms/therapy; T-Lymphocytes; Tumor Cells, Cultured

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy, Active / Cancer Vaccines / Dinitrobenzenes / Haptens / Melanoma Type of study: Clinical_trials Limits: Animals / Female / Humans / Male Language: En Journal: Semin Oncol Year: 1998 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links